BOTHELL, Wash.--(BUSINESS WIRE)--April 11, 2006--Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a patent entitled “Recombinant Anti-CD30 Antibodies and Uses Thereof.” The issued claims cover methods of using certain anti-CD30 antibodies for the treatment of Hodgkin’s disease, both as a single agent and in combination with other therapies. The company currently has two anti-CD30 product candidates in its development pipeline: SGN-30, a genetically engineered antibody, is in phase II clinical development for Hodgkin’s disease and T-cell lymphomas, and SGN-35, an antibody-drug conjugate (ADC), is planned to enter clinical trials during 2006.